https://www.selleckchem.com/products/t0070907.html
To investigate the value of plasma high mobility group box protein 1 (HMGB1) in evaluating the prognosis of cerebral ischemia-reperfusion injury (CIRI) in ischemic stroke patients. 132 ischemic stroke patients were recruited. Before and after thrombolytic therapy at 2h, 6h, 12h, 24h, and 36h, the Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) were recorded. The Modified Rankin scale (mRS) was used to assess the prognosis at 3 months. The NIHSS score, GCS score and plasma HMGB1 level peaked at 6h after t
Like
Comment
Share
